我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

小儿先心病相关肺动脉高压的治疗进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2015年第1期
页码:
118-121
栏目:
综述
出版日期:
2014-09-25

文章信息/Info

Title:
Advances in treatment of pulmonary hypertension associated with congenital heart disease in children
作者:
耿星园1; 2; 刘丽敏1; 徐志懿1; 2; 高秉仁2
(兰州大学：1.第二临床医学院，2.第二附属医院心外一科，甘肃 兰州 730000)
Author(s):
GENG Xing-yuan1; 2;  LIU Li-min1;  XU Zhi-yi1; 2;  GAO Bing-ren2
(1.Second Clinic College, 2.First Department of Cardiac Surgery, Second Affiliated Hospital, Lanzhou University, Lanzhou 730000, Gansu, China)
关键词:
先天性心脏病; 肺动脉高压; 治疗方案; 儿童
Keywords:
congenital heart disease;  pulmonary hypertension;  therapeutic scheme;  children
分类号:
R541.1
DOI:
-
文献标识码:
A
摘要:
先天性心脏病(CHD)是严重危害儿童健康的疾病，由于血流动力学的改变，往往并发肺动脉高压(PAH)。传统的治疗方法以手术为主，随着对PAH认识的深入和诊治技术的进步，PAH-CHD（先心病相关肺动脉高压）的治疗方案也更加多样。本文就PAH-CHD治疗的最新进展作一介绍。
Abstract:
Congenital heart disease (CHD)-related pulmonary hypertension is caused by hemodynamic changes and will in turn intensify the detrimental effects of CHD in terms of childrens' physical health. Traditional surgery is still the main treatment of CHD. However, therapies for CHD-related pulmonary hypertension (PH) become varied due to the contribution of its deeper knowledge and better diagnostic technology. In this review, we will discuss the recent advances in the treatment of CHD and CHD-related PH.

参考文献/References

[1]Galie N,Hoeper MM,Humbert M,et al.Guidelines for the diagnosis and treatment of pulmonary hypertension[J].Eur Respir J,2012, 31(1):71.
[2]D’alto M,Mahadevan VS.Pulmonary arterial hypertension associated with congenital heart disease[J].Eur Respir Rev,2012,21(126):328-337.
[3]Adatia I,Kothari SS,Feinstein JA.Pulmonary hypertension associated with congenital heart disease:pulmonary vascular disease:the global perspective[J].Chest,2010,137(6 Suppl):52S-61S.
[4]Duffels MG,Engelfriet PM,Berger RM,et al.Pulmonary arterial hypertension in congenital heart disease:an epidemiologic perspective from a Dutch registry[J].Int J Cardiol,2007,120(2):198-204.
[5]Levy M,Bonnet D,Mauge L,et al.Circulating endothelial cells in refractory pulmonary hypertension in children:markers of treatment efficacy and clinical worsening[J].PLoS One,2013,8(6):e65114.
[6]Mclaughlin VV,Archer SL,Badesch DB,et al.ACCF/AHA 2009 expert consensus document on pulmonary HypertensionA report of the American college of cardiology foundation task force on expert consensus documents and the American heart association developed in collaboration with the American college of chest physicians;American thoracic society,Inc.;and the pulmonary hypertension association[J].J Am Coll Cardiol,2009, 53(17):1573-1619.
[7]Koestenberger M,Raith W,Ravekes W.Importance of quantifiable right heart systolic function evaluation using tricuspid annular plane systolic excursion(TAPSE)in fetuses and neonates[J].Ultrasound Obstet Gynecol,2013,42(3):367.
[8]Kaemmerer H,Gorenflo M,Hoeper M,et al.Pulmonary arterial hypertension in patients with congenital heart disease: current issues and health care situation[J].Dtsch Med Wochenschr,2013,138(23):1247-1252.
[9]D’alto M,Romeo E,Argiento P,et al.Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology［J］. Int J Cardiol,2012,155(3):378-382.
[10]Baptista R,Castro G,da Silva AM,et al.Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease[J].Revista Portuguesa de Cardiologia,2013,32(2):123-129.
[11]D’alto M,Romeo E,Argiento P,et al.Therapy for pulmonary arterial hypertension due to congenital heart disease and Down’s syndrome[J].Int J Cardiol,2013,164(3):323-326.
[12]Vis JC,Duffels MG,Mulder P,et al.Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease[J].Int J Cardiol,2013,164(1):64-69.
[13]Diller GP,Alonso-Gonzalez R,Dimopoulos K,et al.Disease targeting therapies in patients with Eisenmenger syndrome:response to treatment and long-term efficiency[J].Int J Cardiol,2013,167(3):840-847.
[14]Iversen K,Jensen AS,Jensen TV,et al.Combination therapy with bosentan and sildenafil in Eisenmenger syndrome:a randomized,placebo-controlled, double-blinded trial[J].Eur Heart J,2010,31(9):1124-1131.
[15]Gupta V,Gupta N,Shaik IH,et al.Liposomal fasudil,a rho-kinase inhibitor,for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension[J].J Control Release,2013,167(2):189-199.
[16]Cevik A,Olgunturk R,Kula S,et al.Left-to-Right shunt with congenital heart disease: single center experience[J].ISRN Cardiol,2013,2013:301617.
[17]Haworth SG.Pulmonary hypertension in the young[J].Heart,2002,88(6):658-664.
[18]Balint OH,Samman A,Haberer K,et al.Outcomes in patients with pulmonary hypertension undergoing percutaneous atrial septal defect closure[J].Heart,2008,94(9):1189-1193.
[19]Douwes JM,Roofthooft MT,Bartelds B,et al.Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension[J].Int J Cardiol,2013,168(2):1370-1377.
[20]Jiang X,Jing ZC. Epidemiology of pulmonary arterial hypertension[J].Curr Hypertens Rep,2013,15(6):638-649.

备注/Memo

备注/Memo:
收稿日期：2014-03-21.
通讯作者：高秉仁,教授，主要从事小儿先心病、瓣膜病研究Email：bingrengao@sina.com
作者简介：耿星园,硕士生Email:619593915@qq.com
更新日期/Last Update: 2015-01-20